

Dermatology

Q3 2024


Market Update

The dermatology space continues to see steady transaction volume, albeit at a much slower pace than recent years. The sector has been characterized recently by strategic add-on activity with the majority of deals closed by only a handful of PE-backed consolidators.













PE-backed platforms on their second and third iteration of private equity have been the most active buyers over the last few years. Provident expects that trend to remain and expects that platforms will continue to merge and partner with one another to build scale and regional density in select markets.

Given the trajectory of interest rates, as well as the late stage in the dermatology investment cycle, Provident expects deal volume to experience an upturn over the next few quarters and into 2025.

Quarterly Transaction Volume



Select Transactions

Month	Investor	Target	Physician(s)	Location(s)	State(s)
September			1	1	WA
September			3	3	KY
August			3	1	TX
July			2	1	MA
July			4	2	PA
July			8	6	FL, TX
July			3	1	FL

Provident Industry Coverage Team

AJ Shekar
Director
 (617) 226-4251
 ashekar@providenthp.com

Steve Grassa, CFA
Vice President
 (617) 226-4213
 sgrassa@providenthp.com